Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial – The LancetJune 20, 2023PublicationBy Debbie Everidge0 Comments
0 Impact of Investigational, at-Home, Self-administered, Intranasal Etripamil on the Need for Additional Medical Intervention in Patients With Supraventricular TachycardiaMay 31, 2023PublicationBy Debbie Everidge0 Comments
0 Effect of Etripamil Nasal Spray on Ventricular Rate in Patients Experiencing Symptomatic Atrial Fibrillation: PresentationMay 26, 2023PublicationBy Debbie Everidge0 Comments
0 Effect of Etripamil Nasal Spray on Ventricular Rate in Patients Experiencing Symptomatic Atrial Fibrillation: PosterMay 26, 2023PublicationBy Debbie Everidge0 Comments
Potential New Therapeutic Option for the Treatment of SVT in Acute and Chronic SettingsMay 4, 2023PublicationBy Debbie Everidge0 Comments News in SVT Diagnosis and Management A. John Camm 16th April 2023 EHRA 2023
0 First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301)February 28, 2023PublicationBy Debbie Everidge0 Comments
0 Self-administered Etripamil for Termination of Spontaneous Paroxysmal Supraventricular Tachycardia: Primary Analysis from the RAPID StudyNovember 7, 2022PublicationBy Debbie Everidge0 Comments
0 Long-Term Outcomes of the NODE-302 Study. In the NODE-302 trial, the commonly recorded adverse events were nasal discomfort, nasal congestion, rhinorrhea, epistaxis, sneezing, cough, throat irritation, headache, and increased lacrimation. These adverse events were local and transient.October 3, 2022PublicationBy Debbie Everidge0 Comments
0 Rationale for and design of a multicenter, placebo-controlled, phase 3 study to assess efficacy and safety of intranasal etripamil for the conversion of paroxysmal supraventricular tachycardiaSeptember 20, 2022PublicationBy Debbie Everidge0 Comments
0 Very Low Efficacy of Vagal Maneuvers in Terminating Paroxysmal Supraventricular Tachycardia: Results From the NODE-301 StudyMay 4, 2022PublicationBy Debbie Everidge0 Comments
.png){kind=small}